156% rally in one day! Why this drugmaker stock witnessed such skyrocketing jump on Wall Street
Sellas Life Sciences shares surged 156% after its experimental leukemia vaccine, galinpepimut-S (GPS), significantly extended survival in a late-stage trial. The treatment reduced death risk by 41%, with median survival reaching 24 months. The company plans FDA discussions, targeting an accelerated approval filing in 2027.
Key takeaways
- Category: Stocks.
Why it matters
A routine update. Use the price and stock snapshot to gauge how the market is responding.







